DNBSEQ T7+

October 22, 2025/in MGI, Partners, Sequencing Platforms/by Harshita Sharma

T7+: Ultra-Fast, High-Throughput Sequencing Without Compromise

T7+ is an integrated ultra-high-throughput sequencing platform built for labs that demand speed, accuracy, and scale. Leveraging MGI’s DNBSEQ™ Technology and SM2.0 biochemistry, it delivers over 14Tb of high-quality sequencing data in 24 hours, making large-scale genomics projects—from population studies to clinical pipelines—both feasible and efficient. Its 7-in-1 modular design automates the entire workflow, reducing hands-on time and minimizing potential errors.

Beyond sheer performance, T7+ is engineered with clinical relevance in mind. Its capacity for up to 35,000 whole-genome sequences annually ensures that your lab can meet high-throughput demands without compromising turnaround times. This efficiency directly translates to faster research insights, improved diagnostic workflows, and smoother integration into daily lab operations, helping you focus on what matters most: accurate, actionable genomic data.

>14 Tb/24h ultra-fast sequencing

7-in-1 automation: prep to analysis

QUAD-Flow Cells: PE150 & PE100 simultaneous

Q40 >90% high-quality output

Ergonomic & modular design

Smart system with diagnostics & self-healing

Omni-smart hub guides workflows

Checkpoint resume for uninterrupted runs

Learn more about how each feature works as you scroll.

Watch How T1+ Works

Why It Matters?

Every hour matters when precision, speed, and reliability determine outcomes. T7+ addresses these challenges by combining ultra-high throughput, rapid turnaround, and intelligent automation, so you can focus on results rather than processes.

Get a complete overview of T7+ performance, throughput, workflow automation, and configuration options. For guidance on integrating T7+ into your operations, Decode Science can provide personalized support and local assistance.

DNBSEQ T7+

DNBSEQ-T1+

DNBSEQ-E25

DNBSEQ-G400

DNBSEQ-T7

DNBSEQ-G99

Twist Oncology – DNA CGP Panel

October 9, 2025/in Oncology/by Harshita Sharma

PRODUCTS

Comprehensive Genomic Profiling for Oncology Research

The new Twist Oncology - DNA CGP panel offers 562-gene coverage for complete tumour profiling

Comprehensive Genomic Profiling (CGP) uses next-generation sequencing (NGS) to evaluate multiple clinically relevant biomarkers within a solid tumor. It provides detailed genomic resolution, enabling the detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), select gene fusions, and key cancer genomic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI).

By consolidating this information into a single assay, CGP offers a complete view of a tumor’s molecular profile, reducing the need for multiple tumor-specific panels or separate testing methods.

Why CGP Matters

Unified Testing Platform

Combines samples from all tumor types into a single test platform, enabling efficient batching and streamlined workflow.

Actionable Insights

Focuses on clinically and research-relevant information, supporting treatment decisions and drug development strategies.

Cost-Effective Efficiency

More efficient and economical than whole-exome sequencing (WES) for oncology, lowering resource use while maintaining comprehensive genomic coverage.

If you’d like to see how this fits your current setup, I can walk you through integration options or pilot testing. The new Twist Oncology – DNA CGP Panel provides 562-gene coverage for comprehensive tumor profiling.

Twist Tumor DNA CGP Panel

Enable improved Tx Selection and enhanced Clinical Research

Fixed Panel + Customisation Options

562 genes analyzed for SNVs and hotspot mutations (+39 genes compared to TSO500)
Microsatellite instability (MSI) detection across ~50 sites
Copy number variation (CNV) analysis for 57 clinically relevant genes
Selected fusions and tumor mutational burden (TMB) scoring for complete tumor profiling

Add custom biomarkers to differentiate your lab’s testing capabilities
Adaptable for specific clinical or research needs

End-to-End Twist NGS Workflow Compatibility:

Library preparations: EF2.0, cfDNA
Hybridization solutions with options for software analytics
Streamlined workflow for enhanced lab efficiency

Now available in Australia and New Zealand through Decode Science.

Example Data Metrics

Example sequencing QC metrics averaged across data down sampled to 2000x raw coverage (32M 2×150 reads). 4.5 Gb of Data is enough for VAF detections ranging ~2%. Data available upon request.

Panel target size	2.4 Mb
Example input	50 ng
Mean Target Coverage	515x
On-Target Rate	77%
Fold-80 Base Penalty	1.32
Duplication Rate	20%
Target bases covered >100x	99.5%

Advantages of Twist Oncology Panel

CONTENT

TSO-500 : Content is locked at 523 genes in 2025 and beyond

Twist CGP : Offers an updated CPG panel of 562 genes with Twist dsDNA probes

CUSTOMISATION

TSO-500 : Not Possible

Twist CGP : Can easily modify content to add genomic features or new biomarkers

COMPATIBILITY

TSO-500 : Product is locked into Illumina Platform Ecosystem

Twist CGP : Twist can enable Illumina short-read platforms and non-Illumina platforms (Ultima, Element, etc.)

WORKFLOW

TSO-500 : Requires an overnight capture + 2nd Hybridization Capture

Twist CGP : Single overnight hybridization capture (Option Trinity on Element)

COMPETITIVE PRICING

TSO-500 : High cost per sample for IVD kit pricing

Twist CGP : Can offer competitive pricing and modular kit options.

MODULAR PRODUCT

TSO-500 : Purchase is an all inclusive kit, no option for purchasing components

Twist CGP : Twist can sell modules, or custom configurations through OEM services

Customer Testimonial

"At LifeStrands Genomics Australia, we rely heavily on Twist’s NGS probes and reagents across nearly all our assays... Twist’s probe design flexibility and scalability have allowed us to tailor both DNA and RNA panels that suit a wide range of solid tumours without compromising sensitivity or turnaround times. We view Twist not just as a vendor, but as a strategic partner in advancing precision oncology."

Dr. Vivek Rathi, MD MSc FRCPA

Medical Director LifeStrands Genomics Australia (Genoox User)

Ready To Order?

As the official distributor for Twist Bioscience in Australia and New Zealand, Decode Science makes accessing CGP Panel straightforward. Our role is to connect your lab with Twist’s advanced technologies, ensuring you get the right custom panel solution for your sequencing projects—delivered locally with support when you need it.

DNBSEQ-T1+

October 8, 2025/in MGI, Partners, Sequencing Platforms/by Harshita Sharma

Accelerate high-throughput genomic testing with DNBSEQ-T1+

The DNBSEQ-T1+ is one of the fastest T-level benchtop sequencers available globally—built on MGI’s proven DNBSEQ™ technology for accuracy, scalability, and reliability. Designed for clinical and translational genomics labs, the T1+ supports dual flow cell operation, delivering up to 1.2 terabases (Tb) of sequencing data within 24 hours (600 Gb per flow cell).

For laboratories managing time-sensitive or high-volume projects, this means faster turnaround, improved workflow efficiency, and reduced dependence on external bioinformatics infrastructure. The optional integrated bioinformatics module enables automated secondary analysis immediately after sequencing, helping clinicians and molecular pathologists move from raw data to interpretable results without delay.

In practice, DNBSEQ-T1+ helps streamline comprehensive genomic profiling (CGP), oncology testing, and clinical research pipelines—supporting both diagnostic accuracy and operational consistency across runs.

High-Speed, High-Throughput Sequencing

Generate up to 1.2 Tb of data in a single run with dual flow cell operation.

Choose from FCL, FCM, or FCS flow cells to match your throughput needs—from small clinical batches to large oncology cohorts.

Maintain >93% Q30 and >90% Q40 base quality across read lengths up to PE150.

Complete full runs in as little as 7–24 hours, supporting faster reporting and clinical turnaround.

Versatile Applications Across Clinical Genomics

Flexible read lengths (SE50–PE300) suit NIPT, RNA-Seq, oncology panels, WES, WGS, and methylation studies.

Supports coverage depth from 1 Gb to 120 Gb per sample, enabling both targeted assays and whole-genome workflows.

Ideal for translational and precision medicine—from pathogen detection to tumour profiling.

Integrated DNB Make & Load Technology

DNB M&L (Make & Load) module automates DNB preparation and loading directly within the sequencer.

Delivers consistent, contamination-free results with minimal hands-on time.

Each flow cell operates independently, supporting different read lengths or applications in parallel.

Enables an end-to-end “Make–Sequence–Analyse” workflow that saves time and reduces error.

Smart Configurations and Automated Analysis

Available in two setups: DNBSEQ-T1+ RS (flexible throughput) and T1+ ARS (with built-in bioinformatics).

The ARS configuration automatically triggers advanced data analysis post-run, streamlining bioinformatics pipelines.

Simplifies data interpretation for clinicians and molecular pathologists, improving workflow efficiency and diagnostic accuracy.

Download the DNBSEQ-T1+ brochure for a complete overview of performance metrics, application data, and configuration options. For guidance on how this platform fits your lab’s workflow, Decode Science can walk you through integration and local support options.

Watch How T1+ Works

High Throughput Antibody Production

August 18, 2025/in Partners, Synbio Antibody, Twist/by Harshita Sharma

PRODUCTS

High Throughput Antibody Production

Introducing CHO and HEK293 Antibody Production

Twist Bioscience helps researchers speed up antibody discovery with Express Antibody Production using CHO and HEK293 expression systems. Our high-throughput antibody production platform can generate anywhere from dozens to thousands of antibodies, enabling efficient antibody screening for binding specificity and biophysical properties.

By leveraging Twist’s end-to-end gene-to-protein workflow, you can eliminate common antibody production bottlenecks—saving valuable time and research costs. Starting with Twist Express Genes ensures faster production times and antibodies built entirely from your custom gene sequences.

Key Features

CHO Express Antibodies

From 13 business days*
1 mL and 8 mL scales available
Average Yields = 640 ug

HEK293 Express Antibodies

From 10 business days*
1 mL and 8 mL scales available
Average = Yields 760 ug

Why Twist for Antibody Production?

Customization

Design antibodies with optimal binding affinity, specificity, and reduced immunogenicity.

Speed & Efficiency

Rapid, sequence-perfect DNA synthesis accelerates your antibody development timeline.

Scalable Production

From small-scale studies to large-scale drug discovery, scale antibody production with ease.

Cutting-Edge Technology

Access the latest gene synthesis innovations without high costs.

Expert Support

Get 24/7 guidance from antibody design to submission.

You design it. We build it.

What Scientists Have to Say

Wyatt McDonnell

CEO & Founding Scientist • Infinnimune

Using Twist’s solutions saves us hundreds of thousands of dollars annually in labor costs. The cost efficiency of Twist Express Antibodies allows us to test four times as many antibodies each year as we otherwise could.

Dr. Ahuva Nissim

Professor in Antibody and Therapeutic Engineering • Queen Mary University of London

Working with Twist…was a great experience…[Twist’s] support was amazing. We have performed the first validation selections which looks promising…

Pierre Martineau

Deputy Director, Cancer Research Institute of Montpellier • Founder and Scientific Advisor, iMAb

We have performed the first selections using the Fab and scFv libraries. No problem in both cases, we got clones and some look really promising.

Ready To Order?

Our team can help you in placing the order. Click below to get a quote and fast ordering.

Know More About...

Have a question?

Get a call from your local Decode Science representative to help you find the best fit genomics products for you.

Or give us a call at:

1300 581 991

Cinical Oncology Has new

July 15, 2025/in Uncategorized/by Harshita Sharma

Clinical Blog Update

Updated: Clinical & Pracsoft version 4.3 upgrade and performance improvement tips

From 5 December 2024, Services Australia will no longer support AIR uploads from Clinical V4.2 or earlier.

Over 60% of MedicalDirector Clincial customers are now using version 4.3

We understand that some practices may have encountered challenges when upgrading to Clinical and Pracsoft version 4.3. To help, we’ve compiled a list of suggested actions for your organisation’s System Administrator or IT provider to work through.

If you haven’t upgrade to 4.3 yet, time is running out to remain compliant for AIR uploads from 5 December 2024. Here are some of the other features you’ll benefit from when you upgrade to Clinical & Pracsoft 4.3:

Emails can now be sent with PDF attachments, can be password protected and can be sent directly from the patients file
Revamped Smartbar (formally Sidebar) with the latest Smart Connect Care tools
Add Progress Notes from anywhere in the patient workflow, via a new floating panel
Record a patient’s gender identity and preferred pronouns
A growing range of intelligent tools and marketplace partners appearing within the Smartbar

Learn more and upgrade today

Clinical and Pracsoft version 4.3 IT performance check list

These configurations are important for running software upgrades reliably and may also help improve overall performance, which can be affected by frequent scanning or blocking of MedicalDirector software activity by your IT environment’s rules and configuration.

This broad overview is applicable to a variety of software and hardware scenarios, however should not be considered an all-encompassing solution for your specific healthcare setting. These resources attempt to cover the range of different firewall and antivirus applications available, each with their own method of handling exceptions for permitted files, folders and communications activity.

The procedures outlined for handling exceptions align with industry standards, where software vendors are expected to advise which Ports and URLs need to be accessible, and the site’s Systems Administrator is responsible for interpreting the requirements and applying them appropriately within the context of the environment they are responsible for.

We strongly recommend seeking assistance with configuring your specific firewall and antivirus software by consulting your organisation’s Systems Administrator or IT provider.

Let’s Find You an Application That Helps
Your Research

Get a call from your local Decode Science representative to help you find the best fit genomics products for you.

Or give us a call at:

1300 581 991

Arrayed gRNA Libraries

March 5, 2025/in EditCo, Partners/by Harshita Sharma

PRODUCTS

Arrayed gRNA Libraries

Smarter, Faster, and More Efficient CRISPR Screening

Achieve unparalleled knockout efficiency with EditCo’s multi-guide CRISPR design. Our Arrayed CRISPR gRNA Libraries eliminate the inefficiencies of traditional loss-of-function screens, offering a reliable and ready-to-transfect solution. With up to three spatially coordinated sgRNAs per gene, our approach ensures higher knockout success, reduces false negatives, and eliminates the need for complex NGS data analysis. Designed for both human and mouse genes, our libraries provide fast delivery, robust quality control, and seamless Sanger sequencing analysis—so you can focus on results, not troubleshooting.

Whole Genome CRISPR Libraries for Comprehensive Gene Editing

EditCo’s Whole Human and Whole Mouse Genome Libraries provide unmatched gene coverage with our multi-guide design, ensuring high editing efficiency across 20,000+ gene targets. Designed for seamless transfection, these libraries reduce false negatives and eliminate time-consuming preparation, making large-scale CRISPR screening easier than ever.

– Comprehensive Coverage: Target the entire human or mouse genome with high knockout efficiency.
– Ready-to-Use Libraries: Pre-plated and transfection-ready, minimizing preparation time.
– Enhanced Stability: Chemically modified sgRNAs resist degradation and prevent immune responses.
– Flexible Formats: Available in 96- or 384-well plates with multi-guide sgRNAs for reliable gene disruption.

Accelerate Target Discovery with Pathway Libraries

EditCo’s 30+ Pathway Libraries, including druggable targets, GPCRs, kinases, and immuno-oncology genes, provide a powerful tool for target identification studies. Designed with our multi-guide CRISPR strategy, these libraries ensure high knockout efficiency and fewer false negatives. Select libraries ship in as little as one week, helping you start your screen faster.

– Diverse Pathway Coverage: Includes key gene sets for drug discovery and functional studies.
– Fast Shipping: Select libraries ready to ship within a week.
– High-Efficiency Knockouts: Multi-guide sgRNAs deliver precise, predictable gene disruption.
– Ready-to-Use Format: Available in 96- or 384-well plates with modified sgRNAs for stability.

Available Gene Pathways

Optimal Knockout Efficiency for High-Throughput Screening

XDel technology delivers precise, high-efficiency knockouts by using a multi-guide RNA strategy that ensures consistent and reliable gene editing. Unlike traditional single-guide methods, XDel induces fragment deletions in early exons, maximizing on-target accuracy while minimizing variability and off-target effects.

Superior editing efficiency – Multi-guide design achieves higher and more consistent knockouts
Reduced off-target effects – XDel minimizes unintended edits compared to single-guide methods
Sustained knockout effects – Gene edits remain stable across multiple cell passages
High viability & protein depletion – Maintains cell health while ensuring effective functional knockouts

Achieve robust genotype and phenotype screening with XDel’s optimized CRISPR knockout technology.

Image: XDel multiple gRNA creates fragment deletions

Image: XDel design includes up to 3 modified sgRNAs (grey bars) that target a single gene of interest

Ready to Order?

Our team can help you in placing the order. Click below to get a quote and fast ordering.

Ready to Order?

Gene Knockout kits

Arrayed gRNA Libraries

Let’s Find You an Application That Helps
Your Research

Get a call from your local Decode Science representative to help you find the best fit genomics products for you.

Or give us a call at:

1300 581 991

Gene Knockout Kits

March 4, 2025/in EditCo, Partners/by Harshita Sharma

EditCo Gene Knockout Kits: Reliable and Efficient CRISPR Solutions

EditCo’s Gene Knockout Kit offers a simplified, highly efficient solution for generating human and mouse protein-coding gene knockouts.

Unlike traditional CRISPR methods, which rely on a single guide RNA (gRNA) to create random indels, EditCo’s multi-guide approach ensures consistent and precise gene disruption. This method generates fragment deletions at the targeted loci, providing a more reliable and predictable knockout, ultimately enhancing experimental success.

With fast delivery times (kits arrive in just 5 days), users can avoid the trial and error of guide screening and proceed quickly with their experiments. The process is streamlined further with an easy online ordering portal, which includes the option to purchase controls, SpCas9 nuclease, and Transfection Optimization kits to complement your knockout experiment.

This solution guarantees high knockout efficiency, making gene editing faster and more reliable than ever before.

Why It Matters

Maximise Gene Disruption

XDel’s multi-guide CRISPR design consistently delivers higher on-target editing across multiple loci and cell types. By coordinating 2–3 sgRNAs per exon, researchers can achieve complete functional knockouts with minimal variability.

Precision Editing with Minimal Risk

Off-target edits are a major concern in gene editing. XDel’s cooperative guide approach allows for lower gRNA concentrations while maintaining efficiency, reducing unintended edits and improving experimental reliability.

Persistent Protein Depletion, Straight to Assays

Edited cell pools maintain stable protein loss for weeks, enabling direct use in downstream functional assays. This reduces validation cycles and accelerates your research timelines.

Why Traditional Knockouts Fall Short

Despite its power, CRISPR-Cas9 isn’t foolproof. Most conventional knockout strategies rely on a single guide RNA to induce a small insertion or deletion (indel) at the target site. In theory, this should disrupt the reading frame and deactivate the gene — but in practice, it rarely works that cleanly.

Even minor indels can restore partial functionality or trigger alternative splicing, leaving residual protein activity that undermines downstream results. What should be a “complete knockout” often ends up a mosaic of mixed edits, forcing researchers to spend additional time validating, recloning, or repeating experiments.

And it doesn’t stop there — when working with complex or sensitive cell models like iPSCs, low editing efficiency and variable expression recovery make reproducibility a constant battle. The result? Weeks lost, inconsistent phenotypes, and data that’s difficult to interpret or publish.

Researchers need more than chance-based gene disruption.
They need an approach that targets with precision, edits consistently across cell types, and produces true functional knockouts the first time.

That’s exactly where XDel Technology steps in.

XDel Technology – Coordinated, Multi-Guide Editing

Traditional CRISPR depends on a single cut — a gamble on where repair enzymes will introduce small, random indels. XDel takes a fundamentally smarter approach.

Instead of one guide, XDel uses up to three sgRNAs targeting sites within the same exon. These guides work together to generate coordinated fragment deletions, ensuring the targeted region is fully removed rather than partially disrupted. The result is a true functional knockout — not a mixture of partial edits.

This multi-guide design provides several key advantages:

Higher knockout efficiency: Coordinated cuts increase the likelihood of complete loss of gene function across all alleles.

Cleaner edit outcomes: Large, predictable deletions are easier to confirm with standard PCR or sequencing, reducing downstream validation time.

Compatibility across cell types: Proven performance in immortalized, primary, and iPSC models — even those typically resistant to editing.

By shifting from random indels to engineered deletions, XDel dramatically improves experimental reproducibility and shortens the path from edit design to verified knockout.

Whether your work is in functional genomics, disease modeling, or drug discovery, XDel technology helps you achieve reproducible results faster and with less rework. Decode Science is the official Australian distributor of EditCo. So feel free to reach out to me if you have any questions.

Data-Proven Performance

XDel isn’t theory — it’s backed by real, quantitative data across multiple loci and cell types.

In comparative studies of seven endogenous genes across four different cell lines, XDel’s multi-guide approach consistently outperformed conventional single-guide designs in both knockout efficiency and edit consistency.

1. Higher and More Consistent On-Target Editing

Traditional single-guide methods introduce random indels that often yield partial or incomplete knockouts.
XDel solves this by deploying up to three predesigned sgRNAs targeting a single exon, working together to generate large fragment deletions.
Across seven endogenous loci in four cell lines, this approach achieved significantly higher and more consistent editing efficiencies — reducing the rework often required in CRISPR experiments.

2. Stable Protein Depletion Across Time

Effective gene disruption means sustained loss of protein function, not just transient edits.
In K562 cells, XDel-mediated knockouts of four membrane proteins maintained stable protein depletion for up to 21 days post-editing — with >90% cell viability throughout.
These pools are immediately assay-ready, eliminating the need for additional validation or re-editing.

Click on image to view full size

3. Fewer Off-Target Edits, Greater Precision

A key concern with multi-guide systems is off-target activity — but XDel’s design delivers the opposite.
Rigorous NGS analysis across 63 off-target loci confirmed that XDel edits are more precise than single-guide approaches, showing markedly lower off-target frequencies across both immortalized and iPSC lines.

4. Confirmed Protein Knockout Across Multiple Genes

Western blot analyses for five independent target genes confirmed complete and consistent protein depletion at days 7, 14, and 21 post-transfection.
This demonstrates that XDel doesn’t just produce edits — it reliably eliminates functional protein expression across diverse gene targets.

5. High Editing Efficiency at Lower gRNA Concentrations

The cooperative behavior of XDel’s multi-guide system enables lower total gRNA usage while maintaining exceptional on-target editing rates.
Even when RNP concentrations were reduced to 0.25×, editing remained high with minimal off-target impact — translating to more cost-efficient and cleaner edits.

Applications Across Research Areas

Functional Genomics

Disease Modeling

Drug Discovery and Target Validation

CRISPR Screening and High-Throughput Studies

Talk to Our Specialist

Decode Science is the official distributor of EditCo in Australia and New Zealand, helping researchers access XDel Knockout Technology with local expertise and technical support. Our team works alongside you to identify the right solutions for your workflow — from targeted knockouts to large-scale CRISPR screens — backed by EditCo’s proven data and Decode’s commitment to reproducibility.

For more information or project-specific guidance, reach out to Hamza Hassan, our business development manager, to discuss how XDel can accelerate your next experiment.

CRISPR Reagents Portfolio

Gene Knockout kits

Arrayed gRNA Libraries

Knockout T-cells

March 4, 2025/in EditCo, Partners/by Harshita Sharma

PRODUCTS

Knockout CD8+ & CD4+ T Cells

Advanced CRISPR Knock-Ins for iPSC Research

EditCo delivers efficient gene editing with guaranteed >80% efficiency in human primary cells, achieving >90% in many cases, using a smart multi-guide design and a 7-day protocol for results in 2 weeks or faster. Their Primary Cell KO Pools produce functionally consistent cell populations, ideal for drug discovery or biological modeling, while maintaining high viability and functionality. Researchers can use EditCo-supplied cells or their own CD8+/CD4+ T cells, ensuring flexibility and reliability. By minimizing failed experiments and false negatives, EditCo saves time and resources, offering 1M-cell EC Pools for high-quality, rapid, and dependable gene editing.

Image: High editing efficiency across multiple donors.

Image: EditCo KO CD8+ T cell pools can be thawed and expanded for weeks, with or without TCR stimulation.

Next-Level Edited CD8+ T Cells – Powerful, Stable, and Ready for Action

Take your research further with precision-engineered CD8+ T cells that combine high editing efficiency, long-term stability, and exceptional functionality. Designed to maintain their knockout integrity, expand effortlessly post-thaw, and deliver strong antigen-specific responses, these cells are built for performance. Whether you’re exploring immune responses or advancing cell therapy, these edited T cell pools provide the reliability and power you need.

🔬 Unmatched Editing Precision – Achieve over 90% knockout efficiency across multiple donors, maintaining stability before and after cryopreservation.

🧬 Thrives & Expands with Ease – These cells stay healthy and proliferate for weeks, with or without stimulation, ensuring flexibility in your experiments.

⚡ Optimized for Real-World Function – A single round of activation preserves normal function, preventing overstimulation and exhaustion.

🎯 Potent, Targeted Cytotoxicity – Strong antigen-specific activation, with robust CD107a expression, ensures effective tumor-killing potential.

Power up your research with CD8+ T cells engineered to perform when it matters most.

CD4+ T Cells - Stability and Functionality Post-Editing

The editing of CD4+ T cells has shown high efficiency and stability, with a robust ability to maintain functionality after the editing process. The efficiency of the CD4+ T cell editing was determined through ICE analysis, with results demonstrating high editing efficacy across multiple loci while ensuring cell viability during the freezing stage. Post-editing, the cells can be thawed and expanded without loss of functionality or editing efficiency. Cytokine production in edited T cells, including IFNg, IL2, and TNFa, indicates that the editing process does not negatively impact the cells’ ability to produce essential cytokines upon stimulation. These edited pools also show high viability, making them suitable for further downstream assays.

– High editing efficiency of CD4+ T cells determined by ICE analysis.
– No reduction in cell viability after freezing, as indicated by flow cytometry
– Successful expansion and thawing of edited cells without affecting functionality
– Edited cells exhibit high levels of cytokine production (IFNg, IL2, TNFa) post-stimulation
– High viability and expansion potential, with >90% viability after 14 days in culture
– Statistical analysis shows significant cytokine differences between edited and mock cells

Image: Editing Efficiency and Viability for CD4+ T cell pools.

Image: Editing Efficiency leads to protein depletion as shown by flow cytometry

Image: CD4+ pool stability after thaw.

Ready to Order?

Our team can help you in placing the order. Click below to get a quote and fast ordering.

Let’s Find You an Application That Helps
Your Research

Get a call from your local Decode Science representative to help you find the best fit genomics products for you.

Or give us a call at:

1300 581 991

Knockout Immortalized Cells

February 28, 2025/in EditCo, Partners/by Harshita Sharma

PRODUCTS

Knockout Immortalized Cells

Reliable, Reproducible CRISPR Editing for Breakthrough Discoveries

Spend Less Time on Editing, More on Innovation: EditCo’s advanced automation eliminates time-consuming steps, allowing you to focus on impactful research.

Superior Performance & Scalability: Our CRISPR platform delivers high knockout efficiencies, ensuring consistent, reproducible results across experiments.

XDel Knockout Cell Pools & Clones

XDel is an advanced CRISPR knockout tool that eliminates uncertainty in gene editing. Using a groundbreaking guide RNA design approach, it provides highly effective, reliable, and repeatable gene knockouts, enabling researchers to speed up their breakthroughs with assurance.

– Higher Efficiency & Consistency: XDel technology ensures superior on-target knockout rates with minimal variability.
– Reduced Off-Target Effects: Achieve precise edits with lower unintended mutations compared to single-guide methods.
– Validated & Scalable: Persistent protein depletion enables direct use in functional assays, drug discovery, and disease modeling.

CRISPR Knockout Cell Pools & Clones

Accelerate your research with high-efficiency CRISPR Knockout Cell Pools & Clones from EditCo. Our cell pools provide a mix of edited and unedited cells for immediate assays, while clonal lines ensure precise gene knockouts with sequence-verified accuracy.

– 50%+ knockout efficiency in cell pools
– Up to 95% protein knockout for functional validation
– Single, double, or triple knockouts available
– Comprehensive QC & sequencing reports included

Knockout Cell Libraries – High-Throughput CRISPR Screening Made Easy

EditCo’s Knockout Cell Libraries enable high-efficiency CRISPR screening with over 90% editing success in a ready-to-use 96-well arrayed format. Designed for functional assays and drug target discovery, our libraries eliminate transfection challenges and infrastructure barriers.

– Multi-guide CRISPR design for precise knockouts
– High-throughput screening with scalable workflows
– Comprehensive QC & sequencing reports included
– Compatible with diverse assays for discovery & validation

Ready to Order?

Our team can help you in placing the order. Click below to get a quote and fast ordering.

Immortalized Cells Portfolio

Knockout Immortalized Cells

Knock-in Immortalized Cells

Let’s Find You an Application That Helps
Your Research

Get a call from your local Decode Science representative to help you find the best fit genomics products for you.

Or give us a call at:

1300 581 991

Knock-in iPS Cells

February 28, 2025/in EditCo, Partners/by Harshita Sharma

PRODUCTS

Knock-in iPS Cells

Advanced CRISPR Knock-Ins for iPSC Research

EditCo’s advanced CRISPR knock-ins empower neuroscience, cardiovascular, and regenerative medicine research by delivering precise edits in iPSCs while maintaining their quality, pluripotency, and integrity. Our high-throughput automated platform ensures fast lead times and high editing efficiencies, allowing you to focus on downstream applications like assay development and differentiation.

With minimal off-target effects, our platform offers a range of knock-ins, including single nucleotide variants, tags, and small insertions (<100 bp), available in both homozygous and heterozygous states, as well as in clone or pool formats. Trust EditCo’s robust editing process to accelerate your discoveries with artifact-free, reliable CRISPR-edited iPSCs.

Image: iPS cells were assessed for standard pluripotency markers, three days post-editing.

Single-guide RNA Knock-in Cell Pools

Achieve high-efficiency CRISPR iPSC knock-ins with EditCo’s Knock-in iPS Cell Pools. These pools offer a mix of edited and unedited cells, giving you flexibility for clonal isolation. Our optimized platform ensures precise edits, while you have the option to perform clonal isolation yourself. For those looking for a fully automated process, explore our Knock-in iPS Cell Clones for homogeneity and convenience.

Features:

– Cell Source: EditCo or customer supplied
– Available Edits: SNV, Tag, or Insertion
– CRISPR Design: Synthetic modified sgRNA, Donor ssODN
– Add-ons: QC for pluripotency testing

Deliverables:

– Edited cell pools (2 vials with 5 million cells)
– Regular updates, sequencing data, and comprehensive QC reports

EditCo ensures robust editing with high efficiency across a variety of iPSC lines, maintaining pluripotency and delivering consistent, reliable results.

Single-guide RNA Knock-in Cell Clones

EditCo’s Knock-in iPS Cell Clones provide homogeneous populations derived from single CRISPR-edited cells. Skip the editing and cloning process, and move directly into functional assays with high-quality, reliable clones. We manage the entire CRISPR editing and cloning process, ensuring you receive precise, genetically modified clones for accelerated research.

Features:

– Cell Source: EditCo or customer supplied
– Genetic Modifications: SNV, Tag, or Insertion (Homozygous or Heterozygous)
– CRISPR Design: Synthetic modified sgRNA, Donor ssODN
– Add-ons: Additional clones, QC for pluripotency and karyotype testing

Deliverables:

– 2 independent clones with the required knock-in (2 vials of 500,000 cells each)
– Regular progress updates, sequencing data, and comprehensive QC reports

EditCo ensures precise SNV editing and delivers reliable, pluripotent clones ready for your downstream applications.

Image: 100% SNV editing in iPS cell clones.

Use EditCo’s iPS Cell Lines or Bring Your Own
EditCo provides iPS cell lines for all engineered cell orders at no extra cost. Alternatively, you can onboard your own cell lines.

* Parental vials available for evaluation prior to booking an edit

Ready to Order?

Our team can help you in placing the order. Click below to get a quote and fast ordering.

IPS Cells Portfolio

Knockout iPS Cells

Knock-in iPS Cells

Let’s Find You an Application That Helps
Your Research

Get a call from your local Decode Science representative to help you find the best fit genomics products for you.

Or give us a call at:

1300 581 991

Author Archive for: Harshita

About Harshita Sharma

Entries by Harshita Sharma

>14 Tb/24h ultra-fast sequencing

7-in-1 automation: prep to analysis

QUAD-Flow Cells: PE150 & PE100 simultaneous

Q40 >90% high-quality output

Ergonomic & modular design

Smart system with diagnostics & self-healing

Omni-smart hub guides workflows

Checkpoint resume for uninterrupted runs

Ultra-Fast Sequencing:

Seamless Automation:

Chris Wicky

Smart & Intuitive Operation:

Reliable Data Management:

Versatility for Multi-Omics:

Comprehensive Genomic Profiling for Oncology Research

Unified Testing Platform

Actionable Insights

Cost-Effective Efficiency

Chris Wicky

High-Speed, High-Throughput Sequencing

Versatile Applications Across Clinical Genomics

Integrated DNB Make & Load Technology

Smart Configurations and Automated Analysis

Chris Wicky

High Throughput Antibody Production

Customization

Speed & Efficiency

Scalable Production

Cutting-Edge Technology

Expert Support

Know More About...

Have a question?

Clinical Blog Update

Updated: Clinical & Pracsoft version 4.3 upgrade and performance improvement tips

Clinical and Pracsoft version 4.3 IT performance check list

Let’s Find You an Application That Helps Your Research

Arrayed gRNA Libraries

Smarter, Faster, and More Efficient CRISPR Screening

Let’s Find You an Application That Helps Your Research

EditCo Gene Knockout Kits: Reliable and Efficient CRISPR Solutions

Maximise Gene Disruption

Precision Editing with Minimal Risk

Persistent Protein Depletion, Straight to Assays

Hamza Hassan

Functional Genomics

Disease Modeling

Drug Discovery and Target Validation

CRISPR Screening and High-Throughput Studies

Knockout CD8+ & CD4+ T Cells

Advanced CRISPR Knock-Ins for iPSC Research

Focus on your experiment while they handle CRISPR

Choose your starting point

Transparent and detailed results

Reliable and validated outcomes

Let’s Find You an Application That Helps Your Research

Knockout Immortalized Cells

Reliable, Reproducible CRISPR Editing for Breakthrough Discoveries

Characterize Genes Associated with Neurodegenerative Disease:

Investigate a Protein’s Mechanism of Action:

Expedite Drug Discovery Research:

Thoroughly Confirm Your Phenotype in Multiple Models in Parallel:

Let’s Find You an Application That Helps Your Research

Knock-in iPS Cells

Advanced CRISPR Knock-Ins for iPSC Research

Isogenic Neuronal Lines:

Drug Screening:

Protein Tagging:

Disease Modeling:

Let’s Find You an Application That Helps Your Research

Ready To Order?

Instant Download

Instant Download

Instant Download

Special October Offer

FREE UMBRELLA

Let’s Find You an Application That Helps
Your Research

Let’s Find You an Application That Helps
Your Research

Let’s Find You an Application That Helps
Your Research

Expedite Drug Discovery
Research:

Let’s Find You an Application That Helps
Your Research

Let’s Find You an Application That Helps
Your Research